Atopic Dermatitis Drugs Market By Drug Class and Route of Administration - Global Industry Analysis & Forecast to 2027
Published On : March 2019 Pages : 170 Category: Medical Devices Report Code : HC032756
Atopic Dermatitis Drugs Market By Drug Class (Calcineurin Inhibitors, Biologics, Corticosteroids, PDE4 Inhibitors, Others) Route of Administration (Injectable, Topical, Oral) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Atopic Dermatitis Drugs Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Atopic dermatitis, a sort of dermatitis, is the most widely recognized and long haul provocative skin condition. This incessant sickness causes red and itchy skin. This condition is most basic in youngsters yet can happen at any age. This skin condition is otherwise called atopic dermatitis or dermatitis. It is usually combined with asthma or fever. Different kinds of eczema incorporate dyshidrotic eczema, hand eczema, and contact eczema.
Drivers and Restraints
The market is foreseen to advance at an unobtrusive pace through the gauge time frame. Dispatch of more biologics and little atoms, premium-evaluated medications supplanting nonexclusive first-line and second-line therapeutics, developing frequency of AD, and improved diagnostics are assessed to stir the development of the market. Rising awareness with respect to the accessibility of medications for the illness has helped the market gain footing in the course of recent years.
Regional Insights
Among the seven noteworthy markets, the U.S. overwhelmed the worldwide field in 2017. The U.S. market is foreseen to enroll sound CAGR amid the estimate time frame due to expanding rate of atopic dermatitis.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- LEO Pharma
- Pfizer
- Bayer
- Mylan
- Sanofi
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Atopic Dermatitis Drugs Market, By Drug Class, Estimates and Forecast, 2017-2027 ($Million)
· Calcineurin Inhibitors
· Biologics
· Corticosteroids
· PDE4 Inhibitors
· Others
· Atopic Dermatitis Drugs Market, By Route of Administration, Estimates and Forecast, 2017-2027 ($Million)
· Injectable
· Topical
· Oral
· Atopic Dermatitis Drugs Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
· North America
§ North America Atopic Dermatitis Drugs Market, By Country
o U.S. Atopic Dermatitis Drugs Market
o Canada Atopic Dermatitis Drugs Market
o Mexico Atopic Dermatitis Drugs Market
· Europe
§ Europe Atopic Dermatitis Drugs Market, By Country
o Germany Atopic Dermatitis Drugs Market
o UK Atopic Dermatitis Drugs Market
o France Atopic Dermatitis Drugs Market
o Russia Atopic Dermatitis Drugs Market
o Italy Atopic Dermatitis Drugs Market
o Rest of Europe Atopic Dermatitis Drugs Market
· Asia-Pacific
§ Asia-Pacific Atopic Dermatitis Drugs Market, By Country
o China Atopic Dermatitis Drugs Market
o Japan Atopic Dermatitis Drugs Market
o South Korea Atopic Dermatitis Drugs Market
o India Atopic Dermatitis Drugs Market
o Southeast Asia Atopic Dermatitis Drugs Market
o Rest of Asia-Pacific Atopic Dermatitis Drugs Market
· South America
§ South America Atopic Dermatitis Drugs Market
o Brazil Atopic Dermatitis Drugs Market
o Argentina Atopic Dermatitis Drugs Market
o Columbia Atopic Dermatitis Drugs Market
o Rest of South America Atopic Dermatitis Drugs Market
· Middle East and Africa
§ Middle East and Africa Atopic Dermatitis Drugs Market
o Saudi Arabia Atopic Dermatitis Drugs Market
o UAE Atopic Dermatitis Drugs Market
o Egypt Atopic Dermatitis Drugs Market
o Nigeria Atopic Dermatitis Drugs Market
o South Africa Atopic Dermatitis Drugs Market
o Rest of MEA Atopic Dermatitis Drugs Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Atopic Dermatitis Drugs Market, By Drug Class
5.1. Introduction
5.2. Global Atopic Dermatitis Drugs Revenue and Market Share by Drug Class (2017-2027)
5.2.1. Global Atopic Dermatitis Drugs Revenue and Revenue Share by Drug Class (2017-2027)
5.3. Calcineurin Inhibitors
5.3.1. Global Calcineurin Inhibitors Revenue and Growth Rate (2017-2027)
5.4. Biologics
5.4.1. Global Biologics Revenue and Growth Rate (2017-2027)
5.5. Corticosteroids
5.5.1. Global Corticosteroids Revenue and Growth Rate (2017-2027)
5.6. PDE4 Inhibitors
5.6.1. Global PDE4 Inhibitors Revenue and Growth Rate (2017-2027)
5.7. Others
5.7.1. Global Others Revenue and Growth Rate (2017-2027)
6. Atopic Dermatitis Drugs Market, By Route Of Administration
6.1. Introduction
6.2. Global Atopic Dermatitis Drugs Revenue and Market Share by Route Of Administration (2017-2027)
6.2.1. Global Atopic Dermatitis Drugs Revenue and Revenue Share by Route Of Administration (2017-2027)
6.3. Injectable
6.3.1. Global Injectable Revenue and Growth Rate (2017-2027)
6.4. Topical
6.4.1. Global Topical Revenue and Growth Rate (2017-2027)
6.5. Oral
6.5.1. Global Oral Revenue and Growth Rate (2017-2027)
7. Atopic Dermatitis Drugs Market, By Region
7.1. Introduction
7.2. Global Atopic Dermatitis Drugs Revenue and Market Share by Regions
7.2.1. Global Atopic Dermatitis Drugs Revenue by Regions (2017-2027)
7.3. North America Atopic Dermatitis Drugs by Countries
7.3.1. North America Atopic Dermatitis Drugs Revenue and Growth Rate (2017-2027)
7.3.2. North America Atopic Dermatitis Drugs Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Atopic Dermatitis Drugs by Countries
7.4.1. Europe Atopic Dermatitis Drugs Revenue and Growth Rate (2017-2027)
7.4.2. Europe Atopic Dermatitis Drugs Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Atopic Dermatitis Drugs by Countries
7.5.1. Asia-Pacific Atopic Dermatitis Drugs Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Atopic Dermatitis Drugs Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Atopic Dermatitis Drugs by Countries
7.6.1. South America Atopic Dermatitis Drugs Revenue and Growth Rate (2017-2027)
7.6.2. South America Atopic Dermatitis Drugs Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Atopic Dermatitis Drugs by Countries
7.7.1. Middle East and Africa Atopic Dermatitis Drugs Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Atopic Dermatitis Drugs Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. LEO Pharma
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Pfizer
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Bayer
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Mylan
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Sanofi
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
9. Global Atopic Dermatitis Drugs Market Competition, by Manufacturer
9.1. Global Atopic Dermatitis Drugs Revenue and Market Share by Manufacturer (2017-2017)
9.2. Global Atopic Dermatitis Drugs Price By Region (2017-2017)
9.3. Top 5 Atopic Dermatitis Drugs Manufacturer Market Share
9.4. Market Competition Trend
10. Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.1. Global Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
10.2. Atopic Dermatitis Drugs Market Forecast by Regions (2017-2027)
10.2.1. North America Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.1.1. United States Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.1.2. Canada Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.1.3. Mexico Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.2. Europe Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.2.1. Germany Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.2.2. France Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.2.3. UK Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.2.4. Russia Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.2.5. Italy Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.2.6. Rest of Europe Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.3. Asia-Pacific Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.3.1. China Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.3.2. Japan Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.3.3. Korea Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.3.4. India Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.3.5. Southeast Asia Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.3.6. Rest of Asia-Pacific Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.4. South America Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.4.1. Brazil Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.4.2. Argentina Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.4.3. Columbia Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.4.4. Rest of South America Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.5. Middle East and Africa Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.5.1. Saudi Arabia Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.5.2. United Arab Emirates Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.5.3. Egypt Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.5.4. Nigeria Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.5.5. South Africa Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.5.6. Turkey Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.2.5.7. Rest of Middle East and Africa Atopic Dermatitis Drugs Market Forecast (2017-2027)
10.3. Atopic Dermatitis Drugs Market Forecast by Drug Class (2017-2027)
10.3.1. Atopic Dermatitis Drugs Forecast by Drug Class (2017-2027)
10.3.2. Atopic Dermatitis Drugs Market Share Forecast by Drug Class (2017-2027)
10.4. Atopic Dermatitis Drugs Market Forecast by Route Of Administration (2017-2027)
10.4.1. Atopic Dermatitis Drugs Forecast by Route Of Administration (2017-2027)
10.4.2. Atopic Dermatitis Drugs Market Share Forecast by Route Of Administration (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Atopic Dermatitis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Atopic Dermatitis Drugs Revenue and Revenue Share by Drug Class (2017-2018)
Figure Global Calcineurin Inhibitors Revenue and Growth Rate (2017-2018)
Figure Global Biologics Revenue and Growth Rate (2017-2018)
Figure Global Corticosteroids Revenue and Growth Rate (2017-2018)
Figure Global PDE4 Inhibitors Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Atopic Dermatitis Drugs Revenue and Revenue Share by Route Of Administration (2017-2018)
Figure Global Injectable Revenue and Growth Rate (2017-2018)
Figure Global Topical Revenue and Growth Rate (2017-2018)
Figure Global Oral Revenue and Growth Rate (2017-2018)
Table Global Atopic Dermatitis Drugs Revenue by Regions (2017-2018)
Figure North America Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure North America Atopic Dermatitis Drugs Revenue and Growth Rate (2017-2018)
Figure North America Atopic Dermatitis Drugs by Countries (2017-2018)
Figure North America Atopic Dermatitis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure United States Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure United States Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Canada Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Mexico Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Europe Atopic Dermatitis Drugs Revenue and Growth Rate (2017-2018)
Figure Europe Atopic Dermatitis Drugs by Countries (2017-2018)
Figure Europe Atopic Dermatitis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Germany Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Germany Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure France Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure UK Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Russia Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Italy Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Rest of Europe Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Asia-Pacific Atopic Dermatitis Drugs Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Atopic Dermatitis Drugs by Countries (2017-2018)
Figure Asia-Pacific Atopic Dermatitis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure China Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure China Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Japan Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Korea Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure India Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Southeast Asia Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure South America Atopic Dermatitis Drugs Revenue and Growth Rate (2017-2018)
Figure South America Atopic Dermatitis Drugs by Countries (2017-2018)
Figure South America Atopic Dermatitis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Brazil Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Argentina Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Columbia Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Rest of South America Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Middle East and Africa Atopic Dermatitis Drugs Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Atopic Dermatitis Drugs by Countries (2017-2018)
Figure Middle East and Africa Atopic Dermatitis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Saudi Arabia Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure United Arab Emirates Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Egypt Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Nigeria Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure South Africa Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Turkey Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Atopic Dermatitis Drugs Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Table LEO Pharma Atopic Dermatitis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Pfizer Atopic Dermatitis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Bayer Atopic Dermatitis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Mylan Atopic Dermatitis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Sanofi Atopic Dermatitis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Atopic Dermatitis Drugs Market Share by Manufacturer
Figure Global Atopic Dermatitis Drugs Revenue and Market Share by Manufacturer
Table Global Atopic Dermatitis Drugs Price by Region (2017-2017)
Figure Top 5 Atopic Dermatitis Drugs Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Atopic Dermatitis Drugs Revenue (Millions USD) and Growth Rate (2018-2025)
Table Atopic Dermatitis Drugs Market Forecast by Regions (2018-2025)
Figure North America Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure United States Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Canada Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Mexico Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Europe Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Germany Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure France Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure UK Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Russia Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Italy Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Rest of Europe Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Asia-Pacific Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure China Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Japan Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Korea Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure India Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Southeast Asia Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure South America Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Brazil Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Argentina Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Columbia Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Rest of South America Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Middle East and Africa Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Saudi Arabia Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure United Arab Emirates Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Egypt Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Nigeria Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure South Africa Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Turkey Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Atopic Dermatitis Drugs Market Forecast (2018-2025)
Figure Global Atopic Dermatitis Drugs Forecast by Drug Class (2018-2025)
Figure Global Atopic Dermatitis Drugs Market Share Forecast by Drug Class (2018-2025)
Figure Global Atopic Dermatitis Drugs Forecast by Drug Class (2018-2025)
Figure Global Atopic Dermatitis Drugs Forecast by Route Of Administration (2018-2025)
Figure Global Atopic Dermatitis Drugs Market Share Forecast by Route Of Administration (2018-2025)
Figure Global Atopic Dermatitis Drugs Forecast by Route Of Administration (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|